Evidence map›Paper›PMID 17013468›Full record

Trial reportSaudi medical journal2006

Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin.

Saad A Hussain, Haitham M Khadim, Ban H Khalaf, Sajida H Ismail, Khalid I Hussein, Ahmed S Sahib

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed
In one paragraph

Trial report in Saudi medical journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03848533 (Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes), which is not on this map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03848533 phase2unknown statusstarted 2019, after this paper: background citation

Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes: Pilot Study

Ran2019Enrolled42Registered outcomes19Posted comparisons0ConditionsPrediabetesArmsMelatonin, Metformin, Placebo
PMID 27653034PMID 21241070PMID 20701406PMID 7601013PMID 22722338PMID 17874238PMID 26059289PMID 24792719PMID 24778463PMID 24283301PMID 24251676PMID 23775102other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2010 · on this map
    Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Melatonin, mitochondria, and the metabolic syndrome.Cellular and molecular life sciences : CMLS · 2017
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Saad A HussainDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq. saad_alzaidi@yahoo.com
Haitham M Khadim
Ban H Khalaf
Sajida H Ismail
Khalid I Hussein
Ahmed S Sahib
University of Baghdad · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis project was designed to evaluate the effects of melatonin and zinc on the glycemic control in type 2 diabetes mellitus (T2DM) patients with inadequate response to the oral hypoglycemic agent metformin.

methodsA placebo controlled, double-blind clinical trial was performed at the Specialized Center for Endocrinology and Diabetes, Al-Rusafa Directorate of Health, Baghdad, Iraq during the period from February to July 2005, in which 46 type 2 diabetic patients were selected and allocated into 3 groups, these groups were treated with single daily oral doses of both 10 mg melatonin and 50 mg zinc acetate alone; 10 mg melatonin and 50 mg zinc acetate in addition to the regularly used metformin or placebo, given at bed time for 90 days. We measured the fasting plasma glucose (FPG), glycated hemoglobin (HbA1C) and serum C-peptide before starting the treatment (zero time) and after 30 and 90 days of treatment. We also performed post-prandial glucose excursion test (PPGE) for selected patients from the second and third groups before starting the treatment and after 90 days.

resultsDaily administration of melatonin and zinc improved the impaired fasting and post-prandial glycemic control and decreased the level of glycated hemoglobin; addition of this treatment regimen in combination with metformin improved the tissue responses to this oral hypoglycemic agent.

conclusionThe combination of melatonin and zinc acetate, when used alone or in combination with metformin improves fasting and post-prandial glycemic control in T2DM patients.

Indexed as

Glycated HemoglobinAdultAntioxidantsDiabetes Mellitus, Type 2Double-Blind MethodFemaleHumansHypoglycemic AgentsIraqMaleMelatoninMetforminMiddle AgedZinc AcetateAntioxidantsGlycated HemoglobinHypoglycemic AgentsMelatoninMetforminZinc Acetate

Identifiers

PMID17013468
OpenAlexW2121405025

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.